DaVita (DVA) Expected to Release Earnings on Thursday

DaVita (NYSE:DVA) is expected to be announcing its Q3 2026 results after the market closes on Thursday, October 29th. Analysts expect the company to post earnings of $3.57 per share and revenue of $3.52 billion for the quarter. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. Individuals may visit the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Thursday, October 29, 2026 at 5:00 PM ET.

DaVita (NYSE:DVA) last released its quarterly earnings data on Tuesday, August 4th. The company reported $4.02 earnings per share for the quarter, beating the consensus estimate of $3.88 by $0.14. The company had revenue of $3.55 billion for the quarter, compared to analysts’ expectations of $3.50 billion. The firm’s revenue for the quarter was up 5.2% on a year-over-year basis. During the same period in the previous year, the firm earned $2.95 earnings per share. On average, analysts expect DaVita to post $14.57 EPS for the current fiscal year and $17.25 EPS for the next fiscal year.

DaVita Price Performance

NYSE DVA opened at $181.56 on Wednesday. DaVita has a 1-year low of $101.00 and a 1-year high of $247.49. The business’s fifty day moving average price is $180.70 and its 200-day moving average price is $175.35.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on DVA shares. Weiss Ratings upgraded shares of DaVita from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Friday, October 9th. Raymond James Financial set a $220.00 price target on DaVita in a research report on Friday, August 7th. UBS Group raised their price objective on DaVita from $235.00 to $270.00 and gave the stock a “buy” rating in a research note on Friday, July 10th. TD Cowen reaffirmed a “buy” rating on shares of DaVita in a research report on Wednesday, October 21st. Finally, Truist Financial cut their price objective on DaVita from $250.00 to $215.00 and set a “hold” rating for the company in a research note on Friday, August 7th. Four research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $233.43.

DaVita Company Profile

DaVita Inc (NYSE: DVA) is a health care services company focused on kidney care. Through its DaVita Kidney Care business, the company provides outpatient dialysis treatments for people with chronic kidney failure, including in-center hemodialysis, home dialysis and related clinical support services.

DaVita also offers integrated kidney care programs intended to support patients across the stages of chronic kidney disease. Its services may include care coordination, disease management, education, transplant support and other services designed to improve clinical outcomes and help manage the needs of patients with complex kidney conditions.

The company operates a network of dialysis centers and related facilities in the United States and serves patients in select international markets.